Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance
Reference number: TA161
Published: 27 October 2008
Last updated: 07 February 2018

TA161 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix A - provisional matrix of stakeholders

$TA161 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix A - provisional matrix of stakeholders$

TA161 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix A - provisional matrix of stakeholders
27 August 2013
(102.12 Kb 29 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 23 August 2013